Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1205

1.

Mucosa-associated lymphoid tissue lymphoma of the trachea associated with idiopathic pulmonary fibrosis: A case report and literature review.

Ahn JH, Chung JH, Shin KC, Choi EY, Jin HJ, Choi JH, Lee KH.

Medicine (Baltimore). 2018 May;97(20):e10727. doi: 10.1097/MD.0000000000010727.

2.

Idiopathic Pulmonary Fibrosis.

Lederer DJ, Martinez FJ.

N Engl J Med. 2018 May 10;378(19):1811-1823. doi: 10.1056/NEJMra1705751. Review. No abstract available.

PMID:
29742380
3.

An emerging frontier in the treatment of acute exacerbation of idiopathic pulmonary fibrosis.

Ohshimo S, Costabel U, Shime N.

Respir Investig. 2018 Mar;56(2):97-99. doi: 10.1016/j.resinv.2017.12.003. Epub 2017 Dec 27. No abstract available.

PMID:
29548662
4.

Dental Personnel Treated for Idiopathic Pulmonary Fibrosis at a Tertiary Care Center - Virginia, 2000-2015.

Nett RJ, Cummings KJ, Cannon B, Cox-Ganser J, Nathan SD.

MMWR Morb Mortal Wkly Rep. 2018 Mar 9;67(9):270-273. doi: 10.15585/mmwr.mm6709a2.

5.

Diagnostic criteria for idiopathic pulmonary fibrosis - Authors' reply.

Lynch DA, Sverzellati N, Travis WD, Colby TV, Inoue Y, Nicholson AG, Raoof S, Richeldi L, Ryerson CJ, Ryu JH.

Lancet Respir Med. 2018 Feb;6(2):e7. doi: 10.1016/S2213-2600(18)30021-3. No abstract available.

PMID:
29413090
6.

Diagnostic criteria for idiopathic pulmonary fibrosis.

Fidler L, Shapera S.

Lancet Respir Med. 2018 Feb;6(2):e6. doi: 10.1016/S2213-2600(18)30020-1. No abstract available.

PMID:
29413089
7.

Diagnostic criteria for idiopathic pulmonary fibrosis.

Santos MK, Fabro AT, Baddini-Martinez J.

Lancet Respir Med. 2018 Feb;6(2):e5. doi: 10.1016/S2213-2600(18)30019-5. No abstract available.

PMID:
29413088
8.

Idiopathic pulmonary fibrosis: idiopathic no more?

Thannickal VJ, Wells A, Kolb M.

Lancet Respir Med. 2018 Feb;6(2):84-85. doi: 10.1016/S2213-2600(18)30022-5. No abstract available.

PMID:
29413084
9.

Acupuncture for idiopathic pulmonary fibrosis: Protocol for a systematic review.

Xie Y, Wang JJ, Li GY, Li XL, Li JS.

Medicine (Baltimore). 2017 Dec;96(52):e9114. doi: 10.1097/MD.0000000000009114. Review.

10.

Nintedanib for the treatment of idiopathic pulmonary fibrosis.

Varone F, Sgalla G, Iovene B, Bruni T, Richeldi L.

Expert Opin Pharmacother. 2018 Feb;19(2):167-175. doi: 10.1080/14656566.2018.1425681. Epub 2018 Jan 12. Review.

PMID:
29327616
11.

Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.

Miura Y, Saito T, Tanaka T, Takoi H, Yatagai Y, Inomata M, Nei T, Saito Y, Gemma A, Azuma A.

Respir Investig. 2018 Jan;56(1):72-79. doi: 10.1016/j.resinv.2017.09.007. Epub 2017 Oct 25.

PMID:
29325685
12.

Respiratory comorbidities and risk of mortality in hospitalized patients with idiopathic pulmonary fibrosis.

Oda K, Yatera K, Fujino Y, Kido T, Hanaka T, Sennari K, Fushimi K, Matsuda S, Mukae H.

Respir Investig. 2018 Jan;56(1):64-71. doi: 10.1016/j.resinv.2017.09.006. Epub 2017 Dec 23.

PMID:
29325684
13.

Physical activity in daily life in patients with idiopathic pulmonary fibrosis.

Nishiyama O, Yamazaki R, Sano H, Iwanaga T, Higashimoto Y, Kume H, Tohda Y.

Respir Investig. 2018 Jan;56(1):57-63. doi: 10.1016/j.resinv.2017.09.004. Epub 2017 Oct 23.

PMID:
29325683
14.

Computer-based quantitative computed tomography image analysis in idiopathic pulmonary fibrosis: A mini review.

Ohkubo H, Nakagawa H, Niimi A.

Respir Investig. 2018 Jan;56(1):5-13. doi: 10.1016/j.resinv.2017.10.003. Epub 2017 Dec 7. Review.

PMID:
29325682
15.

Suspected accelerated disease progression after discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: Two case reports.

Okamori S, Asakura T, Masuzawa K, Yasuda H, Kamata H, Ishii M, Betsuyaku T.

Medicine (Baltimore). 2017 Dec;96(49):e9081. doi: 10.1097/MD.0000000000009081.

16.

Triptolide suppresses paraquat induced idiopathic pulmonary fibrosis by inhibiting TGFB1-dependent epithelial mesenchymal transition.

Chen H, Chen Q, Jiang CM, Shi GY, Sui BW, Zhang W, Yang LZ, Li ZY, Liu L, Su YM, Zhao WC, Sun HQ, Li ZZ, Fu Z.

Toxicol Lett. 2018 Mar 1;284:1-9. doi: 10.1016/j.toxlet.2017.11.030. Epub 2017 Nov 28.

PMID:
29195901
17.

Usual interstitial pneumonia: typical, possible, and "inconsistent" patterns.

Torres PPTES, Rabahi MF, Moreira MAC, Meirelles GSP, Marchiori E.

J Bras Pneumol. 2017 Sep-Oct;43(5):393-398. doi: 10.1590/S1806-37562016000000368. English, Portuguese.

18.

Taking a giant step in the diagnosis of idiopathic pulmonary fibrosis.

Tzilas V, Valeyre D, Tzouvelekis A, Bouros D.

Lancet Respir Med. 2018 Feb;6(2):82-84. doi: 10.1016/S2213-2600(17)30443-5. Epub 2017 Nov 15. No abstract available.

PMID:
29154105
19.

Predicting the future of patients with idiopathic pulmonary fibrosis: another step forward.

Luppi F.

Lancet Respir Med. 2017 Dec;5(12):911-913. doi: 10.1016/S2213-2600(17)30436-8. Epub 2017 Nov 14. No abstract available.

PMID:
29150408
20.

Airway expression of Transient Receptor Potential (TRP) Vanniloid-1 and Ankyrin-1 channels is not increased in patients with Idiopathic Pulmonary Fibrosis.

Hutchinson NX, Gibbs A, Tonks A, Hope-Gill BD.

PLoS One. 2017 Nov 17;12(11):e0187847. doi: 10.1371/journal.pone.0187847. eCollection 2017.

Supplemental Content

Loading ...
Support Center